aJohns Hopkins University, Baltimore bAgency for Healthcare Research and Quality, Rockville, Maryland cUniversity of Pennsylvania, Philadelphia, Pennsylvania dOregon Health and Science University, Portland, Oregon, USA.
AIDS. 2013 Aug 24;27(13):2059-68. doi: 10.1097/QAD.0b013e3283623d5f.
Thirty-day hospital readmission rate is receiving increasing attention as a quality-of-care indicator. The objective of this study was to determine readmission rates and to identify factors associated with readmission among persons living with HIV.
Prospective multicenter observational cohort.
Nine US HIV clinics affiliated through the HIV Research Network.
Patients engaged in HIV care during 2005-2010.
MAIN OUTCOME MEASURE(S): Readmission rate was defined as the proportion of hospitalizations followed by a readmission within 30 days. Factors in multivariate analyses included diagnostic categories, patient demographic and clinical characteristics, and having an outpatient follow-up visit.
Among 11,651 total index hospitalizations, the 30-day readmission rate was 19.3%. AIDS-defining illnesses (ADIs, 9.6% of index hospitalizations) and non-AIDS-defining infections (26.4% of index hospitalizations) had readmission rates of 26.2 and 16.6%, respectively. Factors independently associated with readmission included lower CD4 cell count [adjusted odds ratio 1.80 (1.53-2.11) for CD4 cell count <50 vs. ≥351 cells/μl], longer length of stay [1.77 (1.53-2.04) for ≥9 days vs. 1-3 days], and several diagnostic categories including ADI. Having an outpatient follow-up clinic visit was not associated with lower readmission risk [adjusted hazard ratio 0.98 (0.88-1.08)].
The 19.3% readmission rate exceeds the 13.3% rate reported for the general population of 18-64-year-olds. HIV providers may use the 19.3% rate as a basis of comparison. Policymakers may consider the impact of HIV when estimating expected readmissions for a hospital or region. Preventing or recovering from severe immune dysfunction may be the most important factor to reducing readmissions.
30 天住院再入院率作为医疗质量的一个指标,正受到越来越多的关注。本研究的目的是确定再入院率,并确定与艾滋病毒感染者再入院相关的因素。
前瞻性多中心观察队列研究。
9 家通过艾滋病毒研究网络联合的美国艾滋病毒诊所。
2005-2010 年参与艾滋病毒护理的患者。
再入院率定义为住院后 30 天内再次入院的比例。多变量分析中的因素包括诊断类别、患者人口统计学和临床特征,以及门诊随访就诊。
在 11651 例总索引住院中,30 天再入院率为 19.3%。艾滋病定义性疾病(AIDS,占索引住院的 9.6%)和非艾滋病定义性感染(占索引住院的 26.4%)的再入院率分别为 26.2%和 16.6%。与再入院独立相关的因素包括较低的 CD4 细胞计数[调整后的比值比 1.80(1.53-2.11),CD4 细胞计数<50 与≥351 细胞/μl]、较长的住院时间[1.77(1.53-2.04),≥9 天与 1-3 天],以及包括 AIDS 在内的几个诊断类别。门诊随访就诊与再入院风险降低无关[调整后的危险比 0.98(0.88-1.08)]。
19.3%的再入院率超过了 18-64 岁一般人群的 13.3%的再入院率。艾滋病毒提供者可以使用 19.3%的比率作为比较的基础。政策制定者在估计医院或地区的预期再入院率时,可以考虑艾滋病毒的影响。预防或从严重免疫功能障碍中恢复可能是降低再入院率的最重要因素。